腦瘤治療藥的全球市場:2021年~2025年
市場調查報告書
商品編碼
1059033

腦瘤治療藥的全球市場:2021年~2025年

Global Brain Tumor Therapeutics Market 2021-2025

出版日期: | 出版商: TechNavio | 英文 120 Pages | 訂單完成後即時交付

價格
簡介目錄

全球腦瘤治療藥的市場規模在2021年~2025年間,預測將成長到12億3,000萬美元,在預測期間中預計將以9.67%的年複合成長率增長。

市場成長的主要因素有腦腫瘤患病率增加和戰略聯盟。

本報告涵括腦瘤治療藥的全球市場的整體分析,提供市場規模與預測,趨勢,成長要素,課題,及約25供應商的分析。

目錄

摘要整理

市場形勢

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 2020年的市場規模
  • 市場預測:從2020年~2025年的預測

波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者的威脅
  • 替代品的威脅
  • 對手的威脅
  • 市場情況

市場區隔:各類型

  • 市場區隔
  • 各類型的比較
  • 低分子:市場規模與預測(2020年~2025年)
  • 生物學的:市場規模與預測(2020年~2025年)
  • 各類型的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區的比較
  • 北美:市場規模與預測(2020年~2025年)
  • 歐洲:市場規模與預測(2020年~2025年)
  • 亞洲:市場規模與預測(2020年~2025年)
  • 其他地區:市場規模與預測(2020年~2025年)
  • 主要國家
  • 各地區形勢的市場機會
  • 推動市場要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 混亂狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Amgen Inc.
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Emcure Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • NextSource Pharmaceuticals LLC
  • Novartis AG
  • Y-mAbs Therapeutics Inc.

附錄

簡介目錄
Product Code: IRTNTR71849

Technavio has been monitoring the brain tumor therapeutics market and it is poised to grow by $ 1.23 billion during 2021-2025, progressing at a CAGR of 9.67% during the forecast period. Our report on the brain tumor therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of brain cancer and strategic alliances. In addition, the increasing prevalence of brain cancer is anticipated to boost the growth of the market as well.

The brain tumor therapeutics market analysis includes the type segment and geographic landscape.

Technavio's brain tumor therapeutics market is segmented as below:

By Type

  • Small molecules
  • Biologics

By Geographic

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the high morbidity of brain tumorsas one of the prime reasons driving the brain tumor therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on brain tumor therapeutics market covers the following areas:

  • Brain tumor therapeutics market sizing
  • Brain tumor therapeutics market forecast
  • Brain tumor therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading brain tumor therapeutics market vendors that include Amgen Inc., Bristol-Myers Squibb Co., Eisai Co. Ltd., Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., NextSource Pharmaceuticals LLC, Novartis AG, and Y-mAbs Therapeutics Inc. Also, the brain tumor therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Type
    • Market segments
    • Comparison by Type
    • Small molecules - Market size and forecast 2020-2025
    • Biologics - Market size and forecast 2020-2025
    • Market opportunity by Type
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Amgen Inc.
    • Bristol-Myers Squibb Co.
    • Eisai Co. Ltd.
    • Emcure Pharmaceuticals Ltd.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Merck and Co. Inc.
    • NextSource Pharmaceuticals LLC
    • Novartis AG
    • Y-mAbs Therapeutics Inc.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations
  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Type - Market share 2020-2025 (%)
  • 22: Comparison by Type
  • 23: Small molecules - Market size and forecast 2020-2025 ($ million)
  • 24: Small molecules - Year-over-year growth 2020-2025 (%)
  • 25: Biologics - Market size and forecast 2020-2025 ($ million)
  • 26: Biologics - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share By Geographical Landscape 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity By Geographical Landscape ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Amgen Inc. - Overview
  • 48: Amgen Inc. - Business segments
  • 49: Amgen Inc. - Key offerings
  • 50: Amgen Inc. - Key customers
  • 51: Amgen Inc. - Segment focus
  • 52: Bristol-Myers Squibb Co. - Overview
  • 53: Bristol-Myers Squibb Co. - Product and service
  • 54: Bristol-Myers Squibb Co. - Key offerings
  • 55: Bristol-Myers Squibb Co. - Key customers
  • 56: Bristol-Myers Squibb Co. - Segment focus
  • 57: Eisai Co. Ltd. - Overview
  • 58: Eisai Co. Ltd. - Business segments
  • 59: Eisai Co. Ltd. - Key offerings
  • 60: Eisai Co. Ltd. - Key customers
  • 61: Eisai Co. Ltd. - Segment focus
  • 62: Emcure Pharmaceuticals Ltd. - Overview
  • 63: Emcure Pharmaceuticals Ltd. - Product and service
  • 64: Emcure Pharmaceuticals Ltd. - Key offerings
  • 65: Emcure Pharmaceuticals Ltd. - Key customers
  • 66: Emcure Pharmaceuticals Ltd. - Segment focus
  • 67: F. Hoffmann-La Roche Ltd. - Overview
  • 68: F. Hoffmann-La Roche Ltd. - Business segments
  • 69: F. Hoffmann-La Roche Ltd. - Key offerings
  • 70: F. Hoffmann-La Roche Ltd. - Key customers
  • 71: F. Hoffmann-La Roche Ltd. - Segment focus
  • 72: GlaxoSmithKline Plc - Overview
  • 73: GlaxoSmithKline Plc - Business segments
  • 74: GlaxoSmithKline Plc - Key offerings
  • 75: GlaxoSmithKline Plc - Key customers
  • 76: GlaxoSmithKline Plc - Segment focus
  • 77: Merck and Co. Inc. - Overview
  • 78: Merck and Co. Inc. - Business segments
  • 79: Merck and Co. Inc. - Key offerings
  • 80: Merck and Co. Inc. - Key customers
  • 81: Merck and Co. Inc. - Segment focus
  • 82: NextSource Pharmaceuticals LLC - Overview
  • 83: NextSource Pharmaceuticals LLC - Product and service
  • 84: NextSource Pharmaceuticals LLC - Key offerings
  • 85: NextSource Pharmaceuticals LLC - Key customers
  • 86: NextSource Pharmaceuticals LLC - Segment focus
  • 87: Novartis AG - Overview
  • 88: Novartis AG - Business segments
  • 89: Novartis AG - Key offerings
  • 90: Novartis AG - Key customers
  • 91: Novartis AG - Segment focus
  • 92: Y-mAbs Therapeutics Inc. - Overview
  • 93: Y-mAbs Therapeutics Inc. - Business segments
  • 94: Y-mAbs Therapeutics Inc. - Key offerings
  • 95: Y-mAbs Therapeutics Inc. - Key customers
  • 96: Y-mAbs Therapeutics Inc. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations